PDF(Pubmed)
Abstract：
The World Health Organization\'s (WHO) 2022 update on the classification of odontogenic and maxillofacial bone tumors has revolutionized diagnostic and treatment paradigms by integrating novel molecular insights. Fibro-osseous lesions of the maxillo-facial bones constitute a heterogeneous group encompassing fibrous dysplasia, Psammomatoid Ossifying Fibroma (PSOF), Juvenile Trabecular Ossifying Fibroma (JTOF), and other variants. Despite histological similarities, their distinct clinical manifestations and prognostic implications mandate precise differentiation. The intricacies of diagnosing fibro-osseous lesions pose challenges for pathologists, maxillofacial surgeons, dentists and oral surgeons, underscoring the importance of a systematic approach to ensure optimal patient management. Herein, we present two cases, fibrous dysplasia and Cemento-Ossifying Fibroma, detailing their clinical encounters and management strategies. Both patients provided informed consent for publishing their data and images, adhering to ethical guidelines.
摘要：
世界卫生组织（WHO）关于牙源性和颌面骨肿瘤分类的2022更新通过整合新的分子见解，彻底改变了诊断和治疗范式。上颌面部骨骼的纤维骨性病变构成了一个异质组，包括纤维发育不良，砂瘤样骨化性纤维瘤(PSOF),青少年骨小梁纤维化（JTOF），和其他变体。尽管组织学相似，其独特的临床表现和预后意义要求精确鉴别.诊断纤维骨病变的复杂性给病理学家带来了挑战，颌面外科医生,牙医和口腔外科医生，强调系统方法的重要性，以确保最佳的病人管理。在这里，我们提出了两个案例，纤维发育不良和Cemento骨化性纤维瘤，详细介绍他们的临床遭遇和管理策略。两位患者都提供了知情同意书来发布他们的数据和图像，坚持道德准则。
